|
|
|
|
||
Re: I believe it's all about the pricing of KadcylaIndia is on-record that its biosimilar herceptin probably would run about 1/4 the cost of what Roche is presently charging. Here's link to article which shows companies actively involved with biosimilar products. http://gabionline.net/Biosimilars/Research/Biosimilar-trastuzumab-candidates-in-phase-III-development So yes, if push-came-to-shove, more affordable, but still profitable pricing of these products is possible. |
return to message board, top of board |